Mega Genomics Limited (SEHK: 6667)
Health Care · Health Care Providers & Services · CN
HK$7.15
+1.42% today · -1.9% 1Y
Mega Genomics Limited (SEHK: 6667) operates in the Health Care Providers & Services industry within the Health Care sector. The company is valued at $203.35M and employs 196 people.
Over the last twelve months the share price has lost 1.9%, trading between 5.00 and 7.53.
Tweenvest scores Mega Genomics Limited across four factors: quality 69/100, value 37/100, growth 69/100, dividend 60/100. Its strongest factor is quality.
6667 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $203.35M
- Revenue (TTM)
- $52.76M
- P/E
- 49.89
- EPS
- 0.12
- Dividend yield
- 2.46%
- Beta (5Y)
- 0.76
- 52-week high
- HK$7.53
- 52-week low
- HK$5.00
- Avg volume (3M)
- —
- Shares outstanding
- 223.19M
- Employees
- 196
- Next earnings
- —
About Mega Genomics Limited
Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; myocardial infarction and heart failure genetic testing, a service and ancillary service that assesses the genetic risk of developing myocardial infarction and heart failure; cardiovascular and cerebrovascular disease risk assessment packages; hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; RNF180/Septin9 gastric cancer screening test; cervical cancer genetic methylation testing, a cervical cancer test; telomere length genetic testing that assesses the cell age and aging rate of a person; and personal whole genome test plus, a service that assesses the risk of developing multiple types of diseases and provides interpretation for various individual traits and medication advice. It also offers whole exome sequencing package for adults, a service that assesses the risk of developing multiple high-risk diseases, hereditary cancers, recessive genetic diseases, and types of complex diseases, as well as multiple drugs, dietary nutrition items, and exercise and fitness items; folate metabolic capacity assessment testing kits to assess the risk of developing cardiovascular and cerebrovascular diseases; ApoE gene testing for testing Alzheimer’s disease; BRCA1/2 gene mutation testing kits; Alzheimer’s disease screening kits; colorectal cancer screening kits; gastric cancer screening kits; lung nodule auxiliary diagnostic kits; and cervical cancer screening kits to health checkup centers and hospitals. The company was founded in 2016 and is headquartered in Beijing, China.
- ISIN
- KYG5960G1047
- Founded
- 2016
- Listed since
- Jun 22, 2022
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Health Care Providers & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Comjoyful International CompanyOTCPK: KJFI | $211.51M | $— | — |
| Koa Shoji Holdings Co.,Ltd.TSE: 9273 | $211.47M | ¥795.00 | +4.88% |
| Chaoju Eye Care Holdings LimitedSEHK: 2219 | $211.42M | HK$2.39 | +0.63% |
| Scientific and Medical Equipment House CompanySASE: 4014 | $210.30M | SR26.32 | +1.31% |
| Monash IVF Group LimitedASX: MVF | $202.57M | AU$0.75 | +1.36% |
| The Klinique Medical Clinic Public Company LimitedSET: KLINIQ | $198.34M | ฿30.25 | +9.01% |
| Tapdi Oksijen Özel Saglik ve Egitim Hizmetleri Sanayi Ticaret A.S.IBSE: TNZTP | $197.80M | TL24.40 | -4.31% |
| Healius LimitedASX: HLS | $197.63M | AU$0.39 | -1.27% |
Figures last refreshed Oct 11, 2026.